Home » Stocks » PTCT

PTC Therapeutics, Inc. (PTCT)

Stock Price: $42.95 USD -0.22 (-0.51%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $41.65 -1.30 (-3.03%) Jun 11, 5:23 PM
Market Cap 3.03B
Revenue (ttm) 430.45M
Net Income (ttm) -454.12M
Shares Out 70.19M
EPS (ttm) -6.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $42.95
Previous Close $43.17
Change ($) -0.22
Change (%) -0.51%
Day's Open 43.07
Day's Range 42.46 - 43.40
Day's Volume 217,600
52-Week Range 37.12 - 70.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH PLAINFIELD, N.J., June 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic ...

1 day ago - PRNewsWire

SOUTH PLAINFIELD, N.J., June 9, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L.

3 days ago - PRNewsWire

The FDA and the European Commission bestow Orphan Drug status to PTC Therapeutics' (PTCT) PTC923 for the treatment of hyperphenylalaninemia.

2 weeks ago - Zacks Investment Research

SOUTH PLAINFIELD, N.J., May 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) hav...

2 weeks ago - PRNewsWire

SOUTH PLAINFIELD, N.J., May 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conference: William Blair 41st...

3 weeks ago - PRNewsWire

SOUTH PLAINFIELD, N.J., May 17, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from the first study on the impact of caring for a child with the ultra-rare genetic disor...

3 weeks ago - PRNewsWire

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -15.09% and 22.59%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of PTC Therapeutics (NASDAQ:PTCT) were flat after the company reported Q1 results. Quarterly Results Earnings per share were down 1.10% over the past year to ($1.83), which missed the estimate of...

1 month ago - Benzinga

SOUTH PLAINFIELD, N.J., May 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2021.

1 month ago - PRNewsWire

PTC Therapeutics (PTCT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

1 month ago - Zacks Investment Research

SOUTH PLAINFIELD, N.J., April 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: BofA Securities...

1 month ago - PRNewsWire

SOUTH PLAINFIELD, N.J., April 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2021 financi...

1 month ago - PRNewsWire

SOUTH PLAINFIELD, N.J., April 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2021 it approved non-statutory stock options to purchase an aggregate of 75...

1 month ago - PRNewsWire

SOUTH PLAINFIELD, N.J., April 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 ...

1 month ago - PRNewsWire

SOUTH PLAINFIELD, N.J., April 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United States for individuals who ...

1 month ago - PRNewsWire

SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 "Don Clifton Strengths-Based Culture Award" from G...

2 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday,...

2 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., April 1, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™ (r...

2 months ago - PRNewsWire

The European Commission (EC) has granted marketing authorization to PTC Therapeutics Inc's (NASDAQ: PTCT) Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in patients two months an...

Other stocks mentioned: RHHBY
2 months ago - Benzinga

SOUTH PLAINFIELD, N.J., March 30, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the European Commission (EC) has granted marketing authorization to Evrysdi™ (risdiplam)...

2 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., March 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi™ (risdiplam) in children an...

2 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., March 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from a real-world study of patients with Duchenne muscular dystrophy (DMD) and Becker...

2 months ago - PRNewsWire

NEW YORK and SOUTH PLAINFIELD, N.J., March 9, 2021 /PRNewswire/ -- The Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics, Inc. (NASDAQ: PTCT) have entered into a new collaboration focused on...

3 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., Feb. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP...

3 months ago - PRNewsWire

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -20.00% and 4.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

SOUTH PLAINFIELD, N.J., Feb. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the fourth quarter and full year ending December 31, 2020 and provided a...

3 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., Feb. 24, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH study evaluat...

3 months ago - PRNewsWire

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

SOUTH PLAINFIELD, N.J., Feb. 17, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the second stage of the FITE19 clinical trial to assess PTC299 in COVID-19 ...

3 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., Feb. 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call today at 5:30 p.m. E.T. to review results from its clinical study 045 of Translarna...

4 months ago - PRNewsWire

Risk~reward tradeoffs and net payoffs offered by this group are better than those of most S&P 500 Index stocks and of most other Market-Maker [MM] forecast securities. They also outdo the prospects of m...

4 months ago - Seeking Alpha

SOUTH PLAINFIELD, N.J., Jan. 13, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of 13...

4 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., Jan. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its R&D pipeline and commercial progress at the 39th Annual J.P. Morgan Healthcare C...

5 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., Dec. 18, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2020 it approved non-statutory stock options to purchase an aggregate of ...

5 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., Dec. 4, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 2, 2020 it approved non-statutory stock options to purchase an aggregate of 41...

6 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., Dec. 4, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval in the Russian Federation for n...

6 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., Nov. 19, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3rd Annual HealthCONx Conferen...

6 months ago - PRNewsWire

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 6.36% and 11.46%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

SOUTH PLAINFIELD, N.J., Oct. 29, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the third quarter ending September 30, 2020 and provided a corporate upd...

7 months ago - PRNewsWire

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

SOUTH PLAINFIELD, N.J., Oct. 21, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Brazil by the National Health Surveillance Agency (A...

7 months ago - PRNewsWire

ClearPoint Neuro: Becoming The World's Pre-Eminent Neurosurgery Platform

7 months ago - Seeking Alpha

SOUTH PLAINFIELD, N.J., Sept. 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that two-year data from Part 1 of the FIREFISH study demonstrated that infants on Evrysdi™ (r...

8 months ago - PRNewsWire

SOUTH PLAINFIELD, N.J., Sept. 25, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 21, 2020 it approved non-statutory stock options to purchase an aggregate o...

8 months ago - PRNewsWire

PTC Therapeutics (PTCT) gets first commercial milestone payment from Roche for first commercial sale of Evrysdi in the United States.

9 months ago - Zacks Investment Research

PTC Therapeutics??? (PTCT) MAA for Evrysdi is accepted by the European Medicines Agency for the treatment of spinal muscular atrophy.

9 months ago - Zacks Investment Research

PTC Therapeutics hit a milestone in Europe for its drug to treat the rare genetic disease spinal muscular atrophy, triggering a payment from partner Roche and sending PTCT stock rising.

9 months ago - Investors Business Daily

PTC Therapeutics Looks Like A Better Value After Recent Pullback

10 months ago - Seeking Alpha

Roche and PTC Therapeutics will challenge Novartis and Biogen with competitive pricing for Evrysdi.

Other stocks mentioned: RHHBY
10 months ago - The Motley Fool

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the Euro... [Read more...]

Industry
Biotechnology
IPO Date
Jun 20, 2013
CEO
Stuart Peltz
Employees
959
Stock Exchange
NASDAQ
Ticker Symbol
PTCT
Full Company Profile

Financial Performance

In 2020, PTCT's revenue was $380.77 million, an increase of 24.04% compared to the previous year's $306.98 million. Losses were -$438.16 million, 74.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price forecast is 57.22, which is an increase of 33.22% from the latest price.

Price Target
$57.22
(33.22% upside)
Analyst Consensus: Buy